Table 1 |
|||
|
Baseline patient characteristics (N = 2198) |
|||
|
Characteristic |
Serum 25(OH)D levels |
p-value |
|
|
|
|||
|
< = 32 ng/ml (n = 1651) |
> 32 ng/ml (n = 547) |
||
|
|
|||
|
Gender |
|||
|
Males |
628 (77.1) |
186 (22.9) |
Chi-square |
|
Females |
1023 (73.9) |
361 (26.1) |
0.09 |
|
|
|||
|
Age at Presentation |
|||
|
Mean |
55.2 |
55.7 |
2 sample t-test |
|
Median |
55.9 |
55.8 |
0.32 |
|
Range |
18.6 - 92.1 |
21.1 - 89.6 |
|
|
|
|||
|
Treatment history |
|||
|
Newly Diagnosed |
769 (73.2) |
282 (26.8) |
Chi-square |
|
Previously Treated |
882 (76.9) |
265 (23.1) |
0.04 |
|
|
|||
|
Cancer Site |
|||
|
Breast |
347 (69.4) |
153 (30.6) |
|
|
Lung |
268 (81.7) |
60 (18.3) |
|
|
Pancreas |
157 (73.4) |
57 (26.6) |
Chi-square |
|
Colorectal |
174 (85.3) |
30 (14.7) |
< 0.001 |
|
Prostate |
132 (71.4) |
53 (28.6) |
|
|
Others |
573 (74.7) |
194 (25.3) |
|
|
|
|||
|
Stage at Diagnosis |
|||
|
Stage 0 |
21 (75) |
7 (25) |
|
|
Stage 1 |
194 (73.2) |
71 (26.8) |
|
|
Stage 2 |
332 (73.8) |
118 (26.2) |
Chi-square |
|
Stage 3 |
394 (76.7) |
120 (23.3) |
0.76 |
|
Stage 4 |
566 (74.8) |
191 (25.2) |
|
|
Indeterminate |
144 (78.3) |
40 (21.7) |
|
|
|
|||
|
SD = Standard Deviation; Numbers in parenthesis for cancer site, gender, treatment history and stage at diagnosis are row percentages |
|||
|
Vashi et al. Nutrition Journal 2010 9:60 doi:10.1186/1475-2891-9-60 |
|||
